| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002022932 |
| P356 | DOI | 10.1186/S13048-015-0140-8 |
| P932 | PMC publication ID | 4396147 |
| P698 | PubMed publication ID | 25880539 |
| P2093 | author name string | Laila M Poisson | |
| Shailendra Giri | |||
| Calvin Tebbe | |||
| Ramandeep Rattan | |||
| Indrani Datta | |||
| Adnan Munkarah | |||
| Thomas Buekers | |||
| Sharon Hensley-Alford | |||
| Hala Madi | |||
| P2860 | cites work | Applications of metabolomics in cancer research | Q24600728 |
| KEGG for representation and analysis of molecular networks involving diseases and drugs | Q24644514 | ||
| Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 | ||
| Dietary methionine restriction inhibits prostatic intraepithelial neoplasia in TRAMP mice. | Q51050941 | ||
| Polyamine synthesis in rapidly growing tissues. | Q54039425 | ||
| The metabolic defect of methionine dependence occurs frequently in human tumor cell lines | Q71163720 | ||
| Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells | Q73707444 | ||
| Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers | Q85214889 | ||
| Tumour cell survival signalling by the ERK1/2 pathway | Q37290943 | ||
| The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors | Q37594007 | ||
| S-adenosyl methionine specifically protects the anticancer effect of 5-FU via DNMTs expression in human A549 lung cancer cells | Q37641100 | ||
| Roles of LPA in ovarian cancer development and progression | Q37650618 | ||
| Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies | Q37837359 | ||
| Cancer epigenetics reaches mainstream oncology | Q37851012 | ||
| Molecular mechanisms of cisplatin resistance | Q37926477 | ||
| Protein arginine methyltransferases and cancer | Q38067063 | ||
| Role of glutathione in cancer progression and chemoresistance | Q38114436 | ||
| Targeting PI3K/Akt/mTOR Signaling in Cancer | Q38208314 | ||
| A global test for groups of genes: testing association with a clinical outcome | Q38522319 | ||
| Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling | Q39411453 | ||
| Mechanism of action of cis-dichlorodiammineplatinum(II) | Q39811884 | ||
| Analysis of the adult human plasma metabolome | Q40107287 | ||
| Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia | Q40244028 | ||
| Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. | Q40309778 | ||
| Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). | Q40582648 | ||
| Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines | Q41488009 | ||
| Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling | Q44267711 | ||
| Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling | Q44701486 | ||
| Discovery of metabolomics biomarkers for early detection of nephrotoxicity | Q46043673 | ||
| Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy | Q46807097 | ||
| Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer. | Q49057114 | ||
| MetaboAnalyst: a web server for metabolomic data analysis and interpretation | Q24655530 | ||
| Serine, glycine and one-carbon units: cancer metabolism in full circle | Q26828610 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens | Q28143265 | ||
| A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension | Q28260104 | ||
| Cancer cell metabolism: Warburg and beyond | Q28293198 | ||
| Serum methionine metabolites are risk factors for metastatic prostate cancer progression | Q28476490 | ||
| Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy | Q28477131 | ||
| Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer | Q28478197 | ||
| Identification of cisplatin-regulated metabolic pathways in pluripotent stem cells | Q28534469 | ||
| Cellular processing of platinum anticancer drugs | Q29617899 | ||
| Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems | Q33485414 | ||
| DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review) | Q33799002 | ||
| Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells | Q34035257 | ||
| Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform | Q34142972 | ||
| Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine-β-synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro | Q34145385 | ||
| Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy | Q34159386 | ||
| Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma | Q34171626 | ||
| Recognition of cisplatin adducts by cellular proteins | Q34282236 | ||
| The role of glutathione in cancer. | Q34351043 | ||
| Early detection of recurrent breast cancer using metabolite profiling | Q34369288 | ||
| Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer | Q34451931 | ||
| Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression | Q34464915 | ||
| Platinum resistance in breast and ovarian cancer cell lines | Q35397906 | ||
| Methionine dependency and cancer treatment | Q35571234 | ||
| Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation | Q35818950 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases | Q36803757 | ||
| Current status of the polyamine research field | Q36838564 | ||
| DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment | Q37072060 | ||
| Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator | Q37113086 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | platinum | Q880 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 13 | |
| P577 | publication date | 2015-03-26 | |
| P1433 | published in | Journal of Ovarian Research | Q27721898 |
| P1476 | title | A metabolomic approach to identifying platinum resistance in ovarian cancer. | |
| P478 | volume | 8 |
| Q40354565 | Applications of Metabolomics in Cancer Studies |
| Q36411755 | Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer |
| Q97885848 | Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival |
| Q102323905 | Cysteine metabolic circuitries: druggable targets in cancer |
| Q37190310 | Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer |
| Q89292459 | Glutathione in Ovarian Cancer: A Double-Edged Sword |
| Q90043554 | Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders |
| Q36708032 | Metabolic phenotyping for monitoring ovarian cancer patients |
| Q37539378 | Metabolomic Profiling of the Effects of Melittin on Cisplatin Resistant and Cisplatin Sensitive Ovarian Cancer Cells Using Mass Spectrometry and Biolog Microarray Technology |
| Q33844916 | Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells |
| Q58789603 | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
| Q58742209 | Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers |
| Q38689857 | Metabolomics applications in precision medicine: An oncological perspective |
| Q38822368 | Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. |
| Q39529764 | Nutrient Starvation Sensitizes Human Ovarian Cancer SKOV3 Cells to BH3 Mimetic via Modulation of Mitochondrial Dynamics |
| Q93148158 | Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts |
| Q41693933 | Phenotype-driven identification of modules in a hierarchical map of multifluid metabolic correlations |
| Q60912249 | Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning |
| Q37582011 | Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer |
| Q57471599 | Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis |
Search more.